Phase I dose escalation study in patients (pts) with advanced solid tumours receiving first-in-class BI 765063, a selective signal-regulatory protein α (SIRPα) inhibitor, in combination with ezabenlimab (BI 754091), a programmed cell death protein 1 (PD-1) inhibitor

被引：7

作者：

Kotecki, N. ^{[1
]}

Champiat, S. ^{[2
]}

Delord, J-P. ^{[3
]}

Vinceneux, A. ^{[4
]}

Jungels, C. ^{[1
]}

Marabelle, A. ^{[2
]}

Korakis, I. ^{[3
]}

Wojciekowski, S. ^{[5
]}

Block, E. ^{[6
]}

Clarke, N. ^{[7
]}

Fromond, C. ^{[8
]}

Poirier, N. ^{[9
]}

Costantini, D. ^{[10
]}

Vasseur, B. ^{[11
]}

Cassier, P. A. ^{[4
]}

机构：

[1] Inst Jules Bordet, Med Oncol, Brussels, Belgium

[2] Gustave Roussy Canc Campus, Drug Dev Dept DITEP, Villejuif, France

[3] Inst Claudius Regaud, Dept Med Oncol, IUCT Oncopole, Toulouse, France

[4] Ctr Leon Berard, Med Oncol, Lyon, France

[5] Boehringer Ingelheim Pharma GmbH & Co KG, Dept Stat, Biberach, Germany

[6] Boehringer Ingelheim Pharmaceut Inc, Clin Dev, Ridgefield, CT USA

[7] Boehringer Ingelheim Pharma GmBH & Co KG, Translat Med & Clin Pharmacol, Ingelheim, Germany

[8] OSE Immunotherapeut, Preclin Dev & Translat Med, Paris, France

[9] OSE Immunotherapeut, Res Dept, Nantes, France

[10] OSE Immunotherapeut, Early Dev, Paris, France

[11] OSE Immunotherapeut, Immunooncol, Paris, France

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.1367

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

983P

引用

页码：S841 / S842

页数：2

共 50 条

[41] Use of programmed cell death protein 1 (PD-1) inhibitor therapy in HIV-infected patients with advanced cancer: a single-center study from China
Wu, Luling
Su, Jie
Yang, Junyang
Gu, Ling
Zhang, Renfang
Liu, Li
Lu, Hongzhou
Chen, Jun
INFECTIOUS AGENTS AND CANCER, 2023, 18 (01)
[42] A first-in-human phase I dose-escalation study of MK-1496, first-in-class orally available novel PLK1 inhibitor, in patients with advanced solid tumors.
Doi, T.
Murakami, H.
Wan, K.
Miki, M.
Kotani, H.
Sakamoto, N.
Yamamoto, N.
Ohtsu, A.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[43] A dose escalation pharmacokinetic (PK) and pharmacodynamic (PD) study of mTORC1/2 inhibitor XP-105 (BI 860585) as monotherapy and in combination with exemestane or paclitaxel in patients (pts) with advanced solid tumors.
De Braud, Filippo G.
Wu, Wentao Jason
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[44] Phase 1 dose escalation study of DSP107, a first-in-class CD47 and 4-1BB targeting fusion protein, in combination with atezolizumab in patients with advanced solid tumors
Saeed, Anwaar
Bashir, Babar
Luke, Jason J.
Chantre, Reuven
Amsili, Shira
Tabakman, Rinat
Shwartz, Yaffa
Foley-Comer, Adam
Jimeno, Antonio
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[45] First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
Sullivan, Ryan J.
Infante, Jeffrey R.
Janku, Filip
Wong, Deborah Jean Lee
Sosman, Jeffrey A.
Keedy, Vicki
Patel, Manish R.
Shapiro, Geoffrey I.
Mier, James W.
Tolcher, Anthony W.
Wang-Gillam, Andrea
Sznol, Mario
Flaherty, Keith
Buchbinder, Elizabeth
Carvajal, Richard D.
Varghese, Anna M.
Lacouture, Mario E.
Ribas, Antoni
Patel, Sapna P.
DeCrescenzo, Gary A.
Emery, Caroline M.
Groover, Anna L.
Saha, Saurabh
Varterasian, Mary
Welsch, Dean J.
Hyman, David M.
Li, Bob T.
CANCER DISCOVERY, 2018, 8 (02) : 184 - 195
[46] First-in-class oral ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with advanced solid tumors: Final results of a phase I dose escalation and expansion study.
Li, Bob T.
Janku, Filip
Patel, Manish R.
Sullivan, Ryan J.
Flaherty, Keith
Buchbinder, Elizabeth Iannotti
Lacouture, Mario E.
Varghese, Anna M.
Wong, Deborah Jean Lee
Sznol, Mario
Sosman, Jeffrey Alan
Keedy, Vicki Leigh
Wang-Gillam, Andrea
Ribas, Antoni
Tolcher, Anthony W.
Patel, Sapna Pradyuman
Varterasian, Mary Laura
Welsch, Dean
Hyman, David Michael
Infante, Jeffrey R.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[47] AVID200, first-in-class TGF-beta 1 and 3 selective and potent inhibitor: Safety and biomarker results of a phase I monotherapy dose-escalation study in patients with advanced solid tumors.
Yap, Timothy A.
Lakhani, Nehal J.
Araujo, Daniel Vilarim
Ahnert, Jordi Rodon
Chandana, Sreenivasa R.
Sharma, Manish
Denis, Jean-Francois
Gruosso, Tina
Tremblay, Gilles
O'Connor, Maureen
Ghosh, Ria
Sinclair, Sandra
Wood, Debra L.
Nadler, Paul, I
Siu, Lillian L.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[48] A phase 1, open-label, dose-escalation study of PRT1419, a selective induced myeloid leukemia cell differentiation protein (MCL-1) inhibitor, in patients (pts) with advanced/metastatic solid tumors
Falchook, Gerald
Patel, Manish
McKean, Meredith
Philipovskiy, Alexander
Chiaverelli, Rachel
Sun, William
Fossler, Michael
Novotny, William
Kurman, Michael
Rowe, Sarah
Hunter, Deborah
Milhem, Mohammed
CANCER RESEARCH, 2023, 83 (08)
[49] Trial in progress: Phase 1 dose escalation study of T-1101, a first-in-class oral Hec1/Nek2 inhibitor, in patients with advanced refractory solid tumors
Su, Wu-Chou
Bai, Li-Yuan
Hsiao, Hui-Hua
Shiah, Her-Shyong
Yeh, Yu-Min
Chen, Shang-Hung
Wu, Shang-Yin
Wang, Hui-Ching
Tsai, Hui-Jen
Chang, Kwang-Yu
Tsai, Jui-Hung
Lee, Chun-Hui
Lee, Chieh Hua
Chao, Yu-Sheng
Chen, Li-Tzong
CANCER RESEARCH, 2024, 84 (07)
[50] First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363+bevacizumab (beva) in patients (pts) with advanced colorectal cancer (CRC): A phase I study
Lin, Z. Y.
Ma, H.
Liang, X.
Zhao, L.
Yu, D.
Xue, J.
Yang, S.
Hu, J.
Liu, J.
Zhang, D.
Yin, Z.
Yuan, M.
Zhao, L.
Wang, H.
Wei, C.
Ding, L.
Chen, Y.
Zhou, H.
Zhang, T.
ANNALS OF ONCOLOGY, 2024, 35 : S466 - S466

← 1 2 3 4 5 →